Pharmacyclics, Inc. (PCYC) Posts Q2 Loss of 26c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- Wall Street ends down as expectations of Hormuz deal fade
- JPMorgan lifts S&P 500 target to 8,000 on strong earnings
- Nvidia and Wall Street giants plan $500B AI funding deal, FT reports
- Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
- Oil climbs 5% as Iran, US both demand compensation and Hormuz hopes fade
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
Big Beat for Pharmacyclics' (PCYC) Imbruvica - Baird
August 1, 2014 7:18 AM EDTBaird analyst Brian Skorney reiterated an Outperform rating and $173 price target on Pharmacyclics (NASDAQ: PCYC) following Q2 results with Imbruvica putting up a big beat.
"We believe the substantial top-line beat will result in broad increases in consensus estimates as well as a... More
WallachBeth Capital Upgrades Pharmacyclics (PCYC) to Buy
August 1, 2014 6:52 AM EDTWallachBeth Capital upgraded Pharmacyclics (NASDAQ: PCYC) from Hold to Buy.
For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.
Shares of Pharmacyclics closed at $120.44 yesterday.
... More